ORNBV Orion Oyj Class B

Orion Corporation: Organising meeting of the Board of Directors

Orion Corporation: Organising meeting of the Board of Directors

ORION CORPORATION

STOCK EXCHANGE RELEASE / OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE

22 MARCH 2023 at 17.15 EET              

        

Orion Corporation: Organising meeting of the Board of Directors

In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Hilpi Rautelin as Vice Chair.

The compositions of the Board committees were decided to be as follows:



Personnel and Remuneration Committee:

Mikael Silvennoinen, Chair

Maziar Mike Doustdar

Veli-Matti Mattila

Hilpi Rautelin

 

Audit Committee:

Ari Lehtoranta, Chair

Kari Jussi Aho

Eija Ronkainen

Karen Lykke Sørensen

 

R&D Committee:

Hilpi Rautelin, Chair

Kari Jussi Aho

Veli-Matti Mattila

Eija Ronkainen

Karen Lykke Sørensen

 

The Company also has a Nomination Committee, the election of which was announced in a Stock Exchange Release on 29 April 2022. A change in the Nomination Committee composition was announced in a Stock Exchange Release on 21 March 2023.

All members of the Board of Directors have been evaluated to be independent of the company and its significant shareholders.

Orion Corporation

Liisa Hurme



President and CEO
   Olli Huotari



SVP, Corporate Functions
 

                                                

Contact person:

Olli Huotari, Senior Vice President, Corporate Functions

Phone 4

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland



Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.



EN
22/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

337,000 Orion Corporation A shares converted into B shares

337,000 Orion Corporation A shares converted into B shares ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 AUGUST 2025 at 9.00 EEST         337,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 337,000 A shares have been converted into 337,000 B shares. The conversion has been entered into the Trade Register on 20 August 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,971,...

 PRESS RELEASE

337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi ORION OYJ        PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT         20.8.2025 KLO 9.00          337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 337 000 A-osaketta 337 000 B-osakkeeksi. Muuntaminen on merkitty kaupparekisteriin 20.8.2025. Orion Oyj:n osakkeiden kokonaismäärä on 141 134 278 kpl. Muuntamisen jälkeen A-osakkeita on 31 971 783 kpl ja B-osakkeita 109 162 495 kpl. Yhtiön osakkeiden tuottama äänimäärä muunnon jälkeen on yhteensä...

Orion Oyj: 1 director

A director at Orion Oyj sold 4,000 shares at 64.481EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

Orion Corporation: Managers’ transactions – Juhani Kankaanpää ORION CORPORATION MANAGERS’ TRANSACTIONS 8 AUGUST 2025 at 9.30 EEST         Orion Corporation: Managers’ transactions – Juhani Kankaanpää Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Juhani KankaanpääPosition...

 PRESS RELEASE

Orion Oyj: Johtohenkilöiden liiketoimet – Juhani Kankaanpää

Orion Oyj: Johtohenkilöiden liiketoimet – Juhani Kankaanpää ORION OYJ        JOHTOHENKILÖIDEN LIIKETOIMET         8.8.2025 KLO 9.30          Orion Oyj: Johtohenkilöiden liiketoimet – Juhani Kankaanpää Orion Oyj on saanut seuraavan Markkinoiden väärinkäyttöasetuksen (EU) N:o 596/2014 mukaisen ilmoituksen johtohenkilön tai johtohenkilön lähipiirin liiketoimista Orionin osakkeilla tai muilla Orioniin liittyvillä rahoitusvälineillä. Orion Oyj - Johdon liiketoimet____________________________________________IlmoitusvelvollinenNimi: Juhani KankaanpääAsema: Muu ylin johtoLiikkeeseenlaskija: Or...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch